188Re-ZHER2:V2, a promising affibody-based targeting agent against HER2-expressing tumors : preclinical assessment

MLA

Altai, Mohamed, et al. 188Re-ZHER2:V2, a Promising Affibody-Based Targeting Agent against HER2-Expressing Tumors : Preclinical Assessment. 2014. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1233735281&authtype=sso&custid=ns315887.

APA

Altai, M., Wållberg, H., Honarvar, H., Strand, J., Orlova, A., Varasteh, Z., Sandström, M., Löfblom, J., Larsson, E., Strand, S.-E., Lubberink, M., Ståhl, S., & Tolmachev, V. (2014). 188Re-ZHER2:V2, a promising affibody-based targeting agent against HER2-expressing tumors : preclinical assessment.

Chicago

Altai, Mohamed, Helena Wållberg, Hadis Honarvar, Joanna Strand, Anna Orlova, Zohreh Varasteh, Mattias Sandström, et al. 2014. “188Re-ZHER2:V2, a Promising Affibody-Based Targeting Agent against HER2-Expressing Tumors : Preclinical Assessment.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1233735281&authtype=sso&custid=ns315887.